BrainsWay Study Shows 70% Drop in Suicidal Ideation with Deep TMS Treatment
Event summary
- BrainsWay's Deep TMS™ study reduced suicidal ideation by 70% in MDD patients over 6 weeks.
- SWIFT accelerated protocol showed faster improvement (10 days) vs. standard protocol (13 days).
- Study published in Journal of Affective Disorders, building on 2026 research on Deep TMS efficacy.
- FDA cleared BrainsWay's SWIFT protocol for MDD in September 2025, but not for suicidal ideation.
The big picture
BrainsWay's study reinforces Deep TMS as a promising tool in addressing suicidal ideation, a critical unmet need in mental health. The findings align with broader industry trends toward non-invasive treatments for severe depression, positioning BrainsWay as a key player in neurostimulation. The company's ability to leverage this data for regulatory and commercial expansion will be critical in sustaining its leadership.
What we're watching
- Regulatory Expansion
- Whether BrainsWay can secure FDA clearance for suicidal ideation treatment, expanding market potential.
- Clinical Validation
- The pace at which additional studies confirm Deep TMS's role in reducing suicidality.
- Competitive Positioning
- How BrainsWay differentiates itself in the neurostimulation space amid growing research.
Related topics